斯沃在MRSA感染治疗中的地位和价值-课件.ppt

1、患者随机患者随机分组分组(N=1030)金葡菌金葡菌NP*(n=171)治愈无效治愈无效(n=136)MRSA NP(n=85)治愈治愈无效无效(n=62)未用药未用药(n=11)MRSA NP(n=75)治愈无效治愈无效(n=61)金葡菌金葡菌NP(n=168)治愈无效治愈无效(n=136)斯沃斯沃600mg IV q12h(n=524)治愈无效治愈无效(n=417)万古霉素万古霉素1g IV 12h(n=495)治愈无效治愈无效(n=387)比例比例(上皮衬液上皮衬液浓度浓度/血清浓度血清浓度)斯沃斯沃万古霉素万古霉素(63/128)(44/112)(41/90)(31/93)(23/38

2、)(8/35)O N C 3 H F O H C N O O N 1.Adapted from Honeybourne D,et al.J Antimicrob Chemother.2003;51:1431-4 and erratum 2003;52;536.2.Gee T,et al.Antimicrob Agents Chemother.2001;45:1843-6.3.Lovering AC,et al.J Antimicrob Chemother.2002;50:73-7.4.Pfizer Inc.,data on file.5.Gendjar SR,et al.ASN/ISN WCN 2001,Abstract 2205.斯沃的药代动力学斯沃的药代动力学代谢代谢